If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-09. Numbers and descriptions here follow the published literature rather than marketing material.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
=== Hyperrelaxinemia === Premature delivery of relaxin is linked to high levels of relaxin in the mother's bloodstream, known as hyperrelaxinemia. This is caused by the impact of relaxin on the cervix, which disrupts the equilibrium in maintaining the structure of cervical connective tissue. Hyperrelaxinemia caused by ovarian stimulation results in an increased rate of the risk of premature labor and preterm birth.
Studies have shown that a diet high in dairy decreases total body fat. This occurs because a high amount of dietary calcium increases the amount of energy and fat excreted from the body. Other studies have noted that dairy sources of calcium lead to greater weight loss than supplemental calcium intake. This could be due to the bioactive components of dairy sources, especially when combined with a lower calorie diet. Since most natural dairy products contain fat content, there is a common understanding that this may cause weight gain. However, dairy contains ingredients such as whey protein and certain combinations of protein/calcium nutrients that induce a positive effect on satiety, increase energy loss, and assists weight loss.
Immunoaffinity chromatography uses the specific binding of an antibody-antigen to selectively purify the target protein. The procedure involves immobilizing a protein to a solid substrate (e.g. a porous bead or a membrane), which then selectively binds the target, while everything else flows through. The target protein can be eluted by changing the pH or the salinity. The immobilized ligand can be an antibody (such as immunoglobulin G) or it can be a protein (such as protein A). Because this method does not involve engineering in a tag, it can be used for proteins from natural sources.
Radiopharmaceuticals (isotope-labeled drugs) are being developed on an ongoing basis. Radiopharmaceutical residues, such as empty application syringes and contaminated residues from the patient's toilet, shower and washing water, are collected in tanks and stored until they can be safely pumped into the sewer system. The storage time depends on the half-life and ranges from a few weeks to a few months, depending on the radionuclide. Since 2001, by § 29 StrlSchV (in German) of the Radiation Protection Ordinance, the specific radioactivity in the waste containers has been recorded in release measuring stations and the release time is calculated automatically. This requires measurements of the sample activity in Bq/g and the surface contamination in Bq/cm2. In addition, the behavior of the patients after their discharge from the clinic is prescribed. To protect personnel, syringe filling systems, borehole measurement stations for nuclide-specific measurement of low-activity, small volume individual samples, a lift system into the measurement chamber to reduce radiation exposure when handling highly active samples, probe measurement stations, ILP (isolated limb perfusion) measurement stations to monitor activity with one or more detectors during surgery and report leakage to the surgical oncologist.
Sources: en.wikipedia.org
=== Pain === Similarly to μ-opioid receptor (MOR), KOR activation produces antinociceptive effects. KOR agonists are potently analgesic and have been employed clinically for pain management, but they produce characteristic adverse effects which both limit their abuse potential and, unfortunately, their therapeutic utility. The receptor mediates acute thermal and mechanical pain processing. The analgesic actions of KOR occur at both spinal and supraspinal sites. In the spinal cord, presynaptic activation suppresses nociceptive transmission through inhibition of calcium influx and reduction of neurotransmitter release from primary sensory neurons. Neuropathic pain following peripheral nerve injury is accompanied by sustained elevation of dynorphin levels in the spinal dorsal horn, resulting in tonic KOR activation that contributes to pain inhibition. The prodynorphin-derived opioid system within the spinal cord exhibits both pronociceptive and antinociceptive functions. Acute KOR activation produces pain reversal and chronic stimulation leads to receptor tolerance and hyperalgesia with allodynia. Mechanisms such as activation of NMDA receptors on spinal interneurons, and increasing glutamate and substance P release from primary afferent terminals might play a role. KOR also mediates the affective-motivational dimensions of pain. At the supraspinal level, KOR activation in the ventral tegmental area, periaqueductal gray, and other pain-modulatory nuclei influences both pain perception and pain-related motivated behavior.
Decreased appetite Sleep disorder Confusional state Restlessness Libido decreased (including loss of libido) Somnolence Tremor Disturbance in attention Paraesthesia Hypoaesthesia Tachycardia Palpitations Vomiting Dry mouth Diarrhea Hyperhidrosis Muscle spasms Fatigue Asthenia Malaise Feeling abnormal Weight decreased The majority of these reactions were mild or moderate, associated with treatment initiation, and of short duration.
== Organizations == Macedonian Scientific Institute, an institution in Sofia, Bulgaria Marketing Science Institute, a nonprofit learning institution in Cambridge, Massachusetts, US Media Sport Investment, the international fund of investors that ran Sport Club Corinthians Paulista Millennium Science Initiative, an international program bringing technology to developing nations Ministry of Science and Innovation (New Zealand) Minority-serving institution, in US higher education MSI Reproductive Choices, an international non-governmental organisation providing contraception and safe abortion services, with a global HQ in London, UK Museum of Science and Industry (Chicago), US Science and Industry Museum, in Manchester, England University of Minnesota Supercomputing Institute Italian Social Movement (Movimento Sociale Italiano), a defunct post-fascist party
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.